Gemcitabine is a nucleoside analog that has been increasingly used in the chemotherapy of solide tumors, including breast, pancreas ovary and non small cell lung cancer. It is generally well tolerated and has few side effects. Gemcitabine induced pulmonary complications range from mild dyspnea to death from ARDS. A 57- year- old man was treated with six cycles of gemcitabine because of pancreatic carcinoma in July, 2004.The patient had self limiting weakness, lack of appetite, nausea and no dyspnea in treatment period. One year later, he was admitted to a local hospital with exercises induced dyspnea. He had been given levofloxacin for 14 days. On admission to our hospital, his complaint kept on. A few inspiratory crackles were present at r...
Gemcitabine, alone or in combination with a platinum-based agent, is indicated for the first-line tr...
The aim of this phase I/II dose escalating study was to establish the maximum tolerated dose (MTD) o...
Gemcitabine has been widely studied in elderly patients affected by advanced non-small cell lung can...
Gemcitabine was introduced into clinical practice in 1989. This purine analogue anti-metabolite has ...
Gemcitabine is a chemotherapy agent that may cause unpredictable side effects. In this report, we de...
Gemcitabine is a chemotherapeutic agent used for the treatment of a number of malignancies. Although...
Introduction Gemcitabine is a chemotherapeutic agent frequently used by for the treatment of several...
Gemcitabine is the only cytotoxic agent approved by FDA for the treatment of pancreatic carcinoma. G...
SummaryGemcitabine is a newer pyrimidine analog used for the treatment of solid tumors. Though gener...
Gemcitabine is a novel nucleoside analogue with activity in solid tumours. This study assessed the o...
Gemcitabine and docetaxel combination chemotherapy is the standard of care for patients with unresec...
Gemcitabine is a novel nucleoside analogue with activity in solid tumours. This study assessed the o...
Gemcitabine, alone or in combination with a platinum-based agent, is indicated for the first-line tr...
AbstractNew active agents are needed to develop effective systemic therapy against Stage IIIB-IV non...
INTRODUCTION:Newly developed antineoplastic drugs have resulted in improvements in morbidity and mor...
Gemcitabine, alone or in combination with a platinum-based agent, is indicated for the first-line tr...
The aim of this phase I/II dose escalating study was to establish the maximum tolerated dose (MTD) o...
Gemcitabine has been widely studied in elderly patients affected by advanced non-small cell lung can...
Gemcitabine was introduced into clinical practice in 1989. This purine analogue anti-metabolite has ...
Gemcitabine is a chemotherapy agent that may cause unpredictable side effects. In this report, we de...
Gemcitabine is a chemotherapeutic agent used for the treatment of a number of malignancies. Although...
Introduction Gemcitabine is a chemotherapeutic agent frequently used by for the treatment of several...
Gemcitabine is the only cytotoxic agent approved by FDA for the treatment of pancreatic carcinoma. G...
SummaryGemcitabine is a newer pyrimidine analog used for the treatment of solid tumors. Though gener...
Gemcitabine is a novel nucleoside analogue with activity in solid tumours. This study assessed the o...
Gemcitabine and docetaxel combination chemotherapy is the standard of care for patients with unresec...
Gemcitabine is a novel nucleoside analogue with activity in solid tumours. This study assessed the o...
Gemcitabine, alone or in combination with a platinum-based agent, is indicated for the first-line tr...
AbstractNew active agents are needed to develop effective systemic therapy against Stage IIIB-IV non...
INTRODUCTION:Newly developed antineoplastic drugs have resulted in improvements in morbidity and mor...
Gemcitabine, alone or in combination with a platinum-based agent, is indicated for the first-line tr...
The aim of this phase I/II dose escalating study was to establish the maximum tolerated dose (MTD) o...
Gemcitabine has been widely studied in elderly patients affected by advanced non-small cell lung can...